Hydroxysafflor yellow A ameliorates myocardial ischemia/reperfusion injury by promoting MDH1-mediated mitochondrial metabolic homeostasis.

Background: Myocardial ischemia/reperfusion injury (MIRI) is a critical complication in the management of acute myocardial infarction, substantially compromising clinical outcomes. Hydroxysafflor yellow A (HSYA), a natural compound derived from Carthamus tinctorius L., has been approved by the National Medical Products Administration for the management of cardiovascular and cerebrovascular diseases.

Levo-tetrahydropalmatine ameliorates neuropathic pain by inhibiting the activation of the Clec7a-MAPK/NF-κB-NLRP3 inflammasome axis.

Background: Because of the complex pathogenesis of neuropathic pain (NP), the therapeutic efficacy of existing drugs is not satisfactory. Accumulating studies have indicated that neuroinflammation may play a key role in NP onset and progression. Levo-tetrahydropalmatine (l-THP) has been extensively used for relieving chronic pain for decades.